R&D News | pharmaphorum

News

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

News

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

News

Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.

News

AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.

News

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.

News

AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25bn, that will focus on gene-editing therapies.